Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

[1]  Muffy Calder,et al.  When kinases meet mathematics: the systems biology of MAPK signalling , 2005, FEBS letters.

[2]  D. Tuveson,et al.  Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.

[3]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Dirk Strumberg,et al.  Raf Kinase Inhibitors in Oncology , 2005, Oncology Research and Treatment.

[5]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[6]  Channing J Der,et al.  Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? , 2004, Trends in cell biology.

[7]  D. Strumberg,et al.  Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. , 2004, International journal of clinical pharmacology and therapeutics.

[8]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[9]  Tim Eisen,et al.  Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[10]  C. Marshall,et al.  B-RAF is a therapeutic target in melanoma , 2004, Oncogene.

[11]  D. Strumberg,et al.  A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. , 2003, International journal of clinical pharmacology and therapeutics.

[12]  B. Schwartz,et al.  Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. , 2003, International journal of clinical pharmacology and therapeutics.

[13]  M. Flaig,et al.  Mutations of the BRAF gene in benign and malignant melanocytic lesions. , 2003, The Journal of investigative dermatology.

[14]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[15]  J. Sebolt-Leopold,et al.  CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). , 2003, Seminars in oncology.

[16]  I. Chowers,et al.  Lack of BRAF mutation in primary uveal melanoma. , 2003, Investigative ophthalmology & visual science.

[17]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[18]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[19]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[20]  D. Strumberg,et al.  Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. , 2002, International journal of clinical pharmacology and therapeutics.

[21]  M. Stratton,et al.  Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. , 2002, Cancer research.

[22]  B. Riedl,et al.  Design and discovery of small molecules targeting raf-1 kinase. , 2002, Current pharmaceutical design.

[23]  S. Wilhelm,et al.  BAY 43-9006: preclinical data. , 2002, Current pharmaceutical design.

[24]  H. Hirte,et al.  BAY 43-9006: early clinical data in patients with advanced solid malignancies. , 2002, Current pharmaceutical design.

[25]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[26]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[27]  Walter Kolch,et al.  Ras/Raf signalling and emerging pharmacotherapeutic targets , 2002, Expert opinion on pharmacotherapy.

[28]  G. Bollag,et al.  Discovery of a novel Raf kinase inhibitor. , 2001, Endocrine-related cancer.

[29]  E. Lesnik,et al.  Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Sebolt-Leopold,et al.  Biomarker Assays for Phosphorylated MAP Kinase , 2003 .

[31]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[32]  M. J. Arboleda,et al.  Dominant negative mutants of mitogen-activated protein kinase pathway. , 2001, Methods in enzymology.

[33]  Z. Ronai,et al.  K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review. , 2000, Cancer detection and prevention.

[34]  C. Marshall,et al.  Control of the ERK MAP kinase cascade by Ras and Raf. , 1996, Cancer surveys.